AzTrials
AzTrials

Ehlers-Danlos SyndromeFUCHSIA-FRNCT03596437

Study of Arterial Properties by Ultra-high Frequency Ultrasound in Fibromuscular Dysplasia and Vascular Ehlers-Danlos Syndrome

A study testing Ultra High Frequency ultrasound system in people with Ehlers-Danlos Syndrome and Fibromuscular Dysplasia, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Ultra-high frequency ultrasound may be useful in the field of vascular research, given its ability to accurately characterize arterial wall thickness and ultrastructure. In patients with fibromuscular dysplasia (FMD), it may help identify the "triple signal" pattern in carotid arterial wall, while in Vascular Ehlers… Read more about this study

Who is it for?
Ages 18 to 80 years
What is being tested?
Ultra High Frequency ultrasound system
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
90 participants
Where
1 siteFrance
Study dates
7 Jan 2019to Mar 2019
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients aged between 18 and 80 inclusive
  • Patients who have already been diagnosed with FMD of the renal arteries, cervical or cerebral arteries or spontaneous coronary dissections
  • Informed consent signed,
  • Patient affiliated to a social security.
  • Inclusion Criteria for patients with Ehlers-Danlos vascular syndrome:
  • Patients aged between 18 and 80 inclusive
Show all 9Show fewer
  • Patients with a previous diagnosis of vascular Ehlers-Danlos vascular syndrome
  • Informed consent signed,
  • Patient affiliated to a social security.

Who cannot join

  • Persons referred to in Articles L. 1121-5 to L. 1121-8 and L. 1122-12 of the Public Health Code
  • Person subject to an exclusion period for another research
  • Pregnancy in progress
  • Allergies to ultrasound gel or skin lesions (severe eczema, wounds, etc.) that prevent the echo probe from being applied to the area of interest.
  • Refusal or inability to read information, to sign informed consent and not to oppose research, linguistically or psychologically
  • Severe life-threatening disease in the short to medium term

Trial locations and contacts

1 site in 1 country.

Pierre BOUTOUYRIE, PU-PH contact

+33 1 5609 3991

pierre.boutouyrie@aphp.fr

France1 site, 1 recruiting
  • Unité de pharmacologie clinique HEGP

    Paris, 75015

    Pierre BOUTOUYRIE, PU-PH, +33 1 5609 3991, pierre.boutouyrie@aphp.fr

    Hakim KHETTAB, MD, +33 1 5609 2943, hakim.khettab@aphp.fr

    Recruiting

Other trials in France

About this study

Ultra-high frequency ultrasound may be useful in the field of vascular research, given its ability to accurately characterize arterial wall thickness and ultrastructure.

In patients with fibromuscular dysplasia (FMD), it may help identify the "triple signal" pattern in carotid arterial wall, while in Vascular Ehlers Danlos Syndrome (V-EDS) it may help to accurately measure carotid intima-media thickness, which may be extremely small and difficult to measure with standard equipment. Furthermore, novel features might be identified in small-to-medium sized arteries by ultra-high frequency ultrasound.

Read more

The main aim of this study is to demonstrate that ultra-high frequency ultrasound has the same accuracy of standard ultrasound for the identification of "triple signal" in the carotid artery of FMD.

Secondary aims of this study are to evaluate carotid, radial and digital intima-media thickness, wall ultrastructure and distensibility in 60 patients with FMD and in 30 patients with V-EDS.

Read the detailed description

Background: Fibromuscular dysplasia (FMD) is an idiopathic, systemic, non-atherosclerotic, non-inflammatory vascular disease leading to stenosis, aneurysms, dissections and occlusion of small and medium-sized arteries, with possible life-threatening complications. Recent data suggest that FMD is not so rare as previously thought, showing a prevalence up to 4%, but it is mostly undiagnosed. FMD mainly involves renal and internal carotid arteries, thus its clinical manifestations include hypertension and stroke. However, increasing evidence from large registries point out that FMD is a systemic disease, with a very high prevalence of multiple districts involvement.

Vascular Ehlers Danlos Syndrome (V-EDS) is a rare vascular disease (prevalence 1/150000), due to heterozygous mutations of COL3A1 gene, coding for collagen tipe III, with dominant autosomic transmission. V-EDS patients are predisposed to spontaneous ruptures in the vascular, intestinal districts and in many others.

In FMD, vascular subclinical alterations may be observed in usually usually not affected arterial districts, such as the common carotid artery and the radial artery. In a previous experience, Boutouyrie and colleagues discovered a peculiar phenotype in the common carotid artery of individuals with renal FMD. This pattern, known as "triple signal", is characterized by a supernumerary acoustic interface, located between the blood-intima and the media- adventitia interfaces and detected by either the B-mode or the radiofrequency equipment, which may correspond to medial hyperplasia. The "triple signal" pattern, though present in a small proportion of hypertensive patients, was able to accurately discriminate FMD individuals and in particular to identify familiar cases. Furthermore, c-IMT was higher in FMD, while diameter and elasticity were superimposable to hypertensive control group.

Nevertheless, the study of non-affected and easily accessible medium and small-sized arteries, such as the radial artery, with similar diameter and histology of affected arteries such as the renal, cerebral and coronary arteries, might be even more informative in FMD. This has been recently made possible by the commercial availability of ultra-high frequency ultrasound for human use. The machine is equipped with transducers up to 70 MHz and allows imaging superficial tissues with a spatial resolution up to 30 μm (axial) and 65 μm (lateral). Preliminary results by using ultrahigh frequency ultrasound, confirmed an increased radial wall thickness in FMD patients in comparison to age-, sex- and BP-matched controls. Most strikingly, wall ultrastructure was extensively subverted in FMD patients: the two echogenic layers corresponding to the elastic laminae presented a lower echogenicity and a greater inhomogeneity as compared to healthy individuals.

Methods: This is a cross-sectional study, recruiting 60 individuals with FMD and 30 individuals with V-EDS. Patients will be recruited by the Clinical Pharmacology Unit of the Hopital Europeen George Pompidou, during their routine visit for the ultrasound evaluation of the carotid arteries by echotracking. In that occasion, supplementary images of carotid, radial and digital arteries will be acquired by ultrahigh frequency ultrasound (VevoMD; Fujifilm-Visualsonics: Toronto, Canada).

Being tested
Ultra High Frequency ultrasound system
Keywords
Fibromuscular dysplasia, Vascular Ehler-Danlos Syndrome, Ultrasound
Medical subject headings
Ehlers-Danlos Syndrome, Fibromuscular Dysplasia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Ultra High Frequency ultrasound systemDevice

    Also called Vevo MD

    Agreement for carotid intima-media thickness in vascular Ehlers Danlos Syndrome and for triple signal identification in fibromuscular dysplasia will be assessed.

Study groups in NCT03596437
Study groupRoleWhat they receive
Ehlers-Danlos SyndromeExperimentalIntima-media thickness by ultrahigh frequency vs standard ultrasound
Receives: Device: Ultra High Frequency ultrasound system
Fibromuscular DysplasiaExperimentalTriple signal by ultrahigh frequency vs standard ultrasound
Receives: Device: Ultra High Frequency ultrasound system

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Agreement between ultrahigh-frequency and standard ultrasound in the identification of "triple signal" in the common carotid artery wall in fibromuscular dysplasia

    Triple signal is defined as the visual identification of supernumerary acoustic interface in the common carotid artery wall; K statistics will be used.

    Measured: through study completion (an average of 30 minutes)

Secondary outcomes (6)
  1. Agreement between ultrahigh frequency and standard ultrasound in the evaluation of carotid intima-media thickness in fibromuscular dysplasia.

    Measured: through study completion (an average of 30 minutes)

  2. Agreement between ultrahigh frequency and standard ultrasound in the evaluation of carotid intima-media thickness in vascular Ehlers-Danlos syndrome.

    Measured: through study completion (an average of 30 minutes)

  3. Agreement between ultrahigh frequency and standard ultrasound in the evaluation of carotid distensibility in fibromuscular dysplasia.

    Measured: through study completion (an average of 30 minutes)

  4. Agreement between ultrahigh frequency and standard ultrasound in the evaluation of carotid distensibility in vascular Ehlers-Danlos syndrome.

    Measured: through study completion (an average of 30 minutes)

  5. Reproducibility of radial intima-media thickness, measured by ultrahigh frequency ultrasound in fibromuscular dysplasia and vascular Ehlers-Danlos syndrome.

    Intraclass coefficient, correlation at will be used

    Measured: through study completion (an average of 30 minutes)

  6. Reproducibility of radial distensibility, measured by ultrahigh frequency ultrasound in fibromuscular dysplasia and vascular Ehlers-Danlos syndrome.

    Intraclass coefficient, correlation at will be used

    Measured: through study completion (an average of 30 minutes)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Jul 2018
  2. Study start7 Jan 2019
  3. Primary completionMar 2019 (estimated)
  4. Study completionMar 2019 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
90 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03596437
Sponsor's protocol ID
P180201J
Acronym
FUCHSIA-FR
Status last verified
Mar 2019
First submitted
29 May 2018
Last updated
13 Mar 2019
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Ultra High Frequency ultrasound system in people with Ehlers-Danlos Syndrome and Fibromuscular Dysplasia, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 13 Mar 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Pierre BOUTOUYRIE, PU-PH (+33 1 5609 3991, pierre.boutouyrie@aphp.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Agreement between ultrahigh-frequency and standard ultrasound in the identification of "triple signal" in the common carotid artery wall in fibromuscular dysplasia (time frame: through study completion (an average of 30 minutes)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Mar 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in